Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ALEC

ALEC - Alector Inc Stock Price, Fair Value and News

4.92USD+0.22 (+4.68%)Market Closed

Market Summary

ALEC
USD4.92+0.22
Market Closed
4.68%

ALEC Alerts

  • 1 major insider sales recently.
  • Losses in recent quarter

ALEC Stock Price

View Fullscreen

ALEC RSI Chart

ALEC Valuation

Market Cap

474.2M

Price/Earnings (Trailing)

-3.93

Price/Sales (Trailing)

4.92

Price/Free Cashflow

-2.38

ALEC Price/Sales (Trailing)

ALEC Profitability

Return on Equity

-67.42%

Return on Assets

-18.98%

Free Cashflow Yield

-41.93%

ALEC Fundamentals

ALEC Revenue

Revenue (TTM)

96.4M

Rev. Growth (Yr)

-3.96%

Rev. Growth (Qtr)

4.63%

ALEC Earnings

Earnings (TTM)

-120.6M

Earnings Growth (Yr)

21.32%

Earnings Growth (Qtr)

12.92%

Breaking Down ALEC Revenue

Last 7 days

12.6%

Last 30 days

-7.7%

Last 90 days

-19.6%

Trailing 12 Months

-36.2%

How does ALEC drawdown profile look like?

ALEC Financial Health

Current Ratio

3.53

ALEC Investor Care

Shares Dilution (1Y)

15.64%

Diluted EPS (TTM)

-1.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202496.4M000
2023125.7M102.1M96.3M97.1M
2022227.4M300.7M133.2M133.6M
202118.0M21.4M197.9M207.1M
202022.8M19.0M22.2M21.1M
201928.4M28.2M24.4M21.2M
20188.4M15.2M21.6M27.7M
20171.2M2.1M2.9M3.7M
2016000416.0K
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Alector Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
hammond paula
acquired
-
-
35,000
-
Jun 12, 2024
scheller richard h
acquired
-
-
35,000
-
Jun 12, 2024
lavigne louis j jr
acquired
-
-
35,000
-
Jun 12, 2024
wehner david m.
acquired
-
-
35,000
-
Jun 12, 2024
garofalo elizabeth a.
acquired
-
-
35,000
-
Jun 12, 2024
yaffe kristine
acquired
-
-
35,000
-
Jun 03, 2024
romano gary
sold
-38,581
4.7987
-8,040
chief medical officer
Jun 03, 2024
rosenthal arnon
sold
-120,618
4.7988
-25,135
chief executive officer
Jun 03, 2024
kenkare-mitra sara
sold
-63,373
4.7988
-13,206
president and head of r&d
Jun 03, 2024
grasso marc
sold
-33,207
4.7988
-6,920
chief financial officer

1–10 of 50

Which funds bought or sold ALEC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-179,000
605,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
89.08
32,786
110,786
0.01%
May 16, 2024
COMERICA BANK
unchanged
-
-42.00
126
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
0.95
-126,375
403,689
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-65.4
-621,707
219,585
-%
May 15, 2024
PDT Partners, LLC
added
415
257,298
346,331
0.03%
May 15, 2024
AMUNDI
added
162
98,398
248,993
-%
May 15, 2024
Capital Impact Advisors, LLC
reduced
-76.01
-669,137
147,863
0.19%
May 15, 2024
Voya Investment Management LLC
reduced
-14.26
-73,122
133,927
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-94.25
-116,640
5,286
-%

1–10 of 47

Are Funds Buying or Selling ALEC?

Are funds buying ALEC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALEC
No. of Funds

Unveiling Alector Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.21%
4,386,541
SC 13G/A
Feb 12, 2024
morgan stanley
5.5%
4,605,044
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
polaris venture partners vi, l.p.
0.5%
498,468
SC 13G/A
Feb 08, 2024
rosenthal arnon
-
7,285,773
SC 13G
Jan 24, 2024
blackrock inc.
9.6%
8,068,553
SC 13G/A
Oct 13, 2023
fmr llc
-
0
SC 13G/A
Oct 10, 2023
fil ltd
-
0
SC 13G/A
Feb 10, 2023
ecor1 capital, llc
4.9%
4,056,548
SC 13G/A
Feb 10, 2023
rosenthal arnon
-
6,884,362
SC 13G/A

Recent SEC filings of Alector Inc

View All Filings
Date Filed Form Type Document
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
4
Insider Trading
Jun 12, 2024
8-K
Current Report
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading

Peers (Alternatives to Alector Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.95
10.1
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.84
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.89
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.85
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.07
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Alector Inc News

Latest updates
MarketBeat31 hours ago
Investing.com04 Jun 202410:18 pm

Alector Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue4.6%16.0015.009.0056.0017.0014.0015.0080.0024.0014.001827.004.005.006.003.007.006.003.007.006.00
Operating Expenses-4.9%60.0063.0060.0060.0067.0070.0063.0070.0069.0070.0056.0062.0057.0058.0060.0050.0049.0038.0037.0034.0026.00
  S&GA Expenses-3.3%14.0015.0013.0014.0015.0015.0014.0016.0016.0017.0013.0014.0011.0013.0016.0016.0015.0013.008.008.006.00
  R&D Expenses-5.4%45.0048.0046.0046.0052.0054.0048.0055.0053.0053.0043.0048.0046.0044.0044.0034.0035.0026.0029.0026.0021.00
Income Taxes-99.6%0.002.001.001.001.001.001.001.001.00------------
Net Income12.9%-36.08-41.43-44.471.00-45.86-52.43-46.1510.00-44.62-55.61127-55.15-52.17-52.18-52.70-45.33-40.02-30.53-31.74-24.56-18.56
Net Income Margin6.9%-1.25*-1.34*-1.47*-1.40*-1.07*-1.00*-1.02*0.12*-0.13*-0.18*-0.17*-9.90*---------
Free Cashflow-33.6%-61.88-46.30-46.45-44.22-49.57-49.69-50.97-58.19134-49.82444-45.37---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets2.2%635622672709748788837890954815854397440488532572619422450477496
  Current Assets2.8%581566613648686726775827891750788329375422470510556357385415442
    Cash Equivalents-2.7%73.0075.0010213219615618417245533151712611151.0085.0093.0016191.0087.0069.0061.00
  Net PPE-4.7%21.0022.0023.0024.0025.0026.0026.0026.0026.0027.0028.0029.0029.0030.0031.0032.0033.0034.0034.0032.0022.00
Liabilities-6.4%457488510512565573584601687514518213213221221217227227231232230
  Current Liabilities-7.3%16517815513299.0094.0016114914314013374.0064.0068.0071.0066.0072.0062.0059.0067.0056.00
Shareholder's Equity33.4%179134163196183214253289268301336185228268310355392195219246266
  Retained Earnings-5.1%-746-710-668-624-625-579-527-481-490-446-390-517-462-410-357-305-259-219-189-157-132
  Additional Paid-In Capital9.6%925844832822811799787776762748727702690677667659649414408403399
Shares Outstanding13.6%96.0085.0084.0084.0083.0083.0083.0082.0082.0080.0080.0080.00---------
Float----384---627---1,193---1,376---549-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-33.2%-61,346-46,070-46,540-43,004-48,548-48,925-49,053-57,442135,091-49,265445,052-44,543-52,693-47,658-40,821-45,942-32,313-28,827-28,863-18,052-23,566
  Share Based Compensation-10.7%10,30711,54210,05910,22210,97510,96310,76612,47811,93912,70610,2019,0788,8008,9028,0306,9486,6425,2384,1043,6943,245
Cashflow From Investing-165.1%-11,76518,07116,961-21,81588,70118,38160,530-225,819-12,106-146,753-69,05456,591109,55311,55233,013-24,744-124,87230,05745,90926,422-151,262
Cashflow From Financing11952.2%71,108590-8811,0796364899062,4838,63814,8212,9623,8741,0962862,270228,4611,437720-116170,312
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ALEC Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue$ 15,893$ 16,549
Operating expenses:  
Research and development45,16751,887
General and administrative14,43414,777
Total operating expenses59,60166,664
Loss from operations(43,708)(50,115)
Other income, net7,6365,159
Loss before income taxes(36,072)(44,956)
Income tax expense7901
Net loss(36,079)(45,857)
Unrealized gain (loss) on marketable securities(587)2,376
Comprehensive loss$ (36,666)$ (43,481)
Net loss per share, basic$ (0.38)$ (0.55)
Net loss per share, diluted$ (0.38)$ (0.55)
Shares used in computing net loss per share, basic93,810,17783,102,296
Shares used in computing net loss per share, diluted93,810,17783,102,296

ALEC Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 72,552$ 74,555
Marketable securities489,531474,306
Prepaid expenses and other current assets19,30716,946
Total current assets581,390565,807
Property and equipment, net20,83521,861
Operating lease right-of-use assets24,32125,195
Restricted cash1,5461,546
Other assets7,4027,418
Total assets635,494621,827
Current liabilities:  
Accounts payable4,5863,775
Accrued clinical supply costs5,8705,215
Accrued liabilities19,38530,378
Deferred revenue, current portion73,35282,975
Payable to collaboration partner15,6327,703
Refund liability to collaboration partner, current portion37,55739,440
Operating lease liabilities, current portion8,5358,462
Total current liabilities164,917177,948
Deferred revenue, long-term portion204,575210,845
Refund liability to collaboration partner, long-term portion56,70067,047
Operating lease liabilities, long-term portion29,02230,456
Other long-term liabilities1,3731,373
Total liabilities456,587487,669
Commitments and contingencies (Note 4)
Stockholders' equity:  
Common stock, $0.0001 par value; 200,000,000 shares authorized; 96,384,562 and 84,879,693 shares issued and outstanding as of March 31, 2024 and December 31, 202398
Additional paid-in capital925,458844,044
Accumulated other comprehensive income (loss)(403)184
Accumulated deficit(746,157)(710,078)
Total stockholders' equity178,907134,158
Total liabilities and stockholders’ equity$ 635,494$ 621,827
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEalector.com
 INDUSTRYBiotechnology
 EMPLOYEES239

Alector Inc Frequently Asked Questions


What is the ticker symbol for Alector Inc? What does ALEC stand for in stocks?

ALEC is the stock ticker symbol of Alector Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alector Inc (ALEC)?

As of Thu Jun 13 2024, market cap of Alector Inc is 474.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers.

What is the fair value of ALEC stock?

You can check ALEC's fair value in chart for subscribers. The fair value of Alector Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alector Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALEC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alector Inc a good stock to buy?

The fair value guage provides a quick view whether ALEC is over valued or under valued. Whether Alector Inc is cheap or expensive depends on the assumptions which impact Alector Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALEC.

What is Alector Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, ALEC's PE ratio (Price to Earnings) is -3.93 and Price to Sales (PS) ratio is 4.92. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALEC PE ratio will change depending on the future growth rate expectations of investors.